Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02517502 · ClinicalTrials.gov registry record · Early Phase 1
Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy
A Early Phase 1 study of Cognitive Dysfunction, sponsored by Carol Fabian, MD.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT02517502 is a Early Phase 1 study of Cognitive Dysfunction that has completed, run by Carol Fabian, MD. The registered enrollment target is 24 participants, below the 1,992-participant average among 45 other Cognitive Dysfunction trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02517502, a Early Phase 1 study of Cognitive Dysfunction, has completed, sponsored by Carol Fabian, MD.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine if a high dose of DHA begun prior to and continued during neo-adjuvant chemotherapy (chemotherapy given prior to surgery) is likely to prevent or lessen chemotherapy induced cognitive dysfunction.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG DHA
Study Locations (2)
Illinois
- Decatur Memorial Hospital - Decatur
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-07 |
| Est. Completion | 2019-05-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02517502
The ClinicalTrials.gov registry entry for NCT02517502 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,992-participant average among 45 other Cognitive Dysfunction trials with a reported enrollment target (99% lower). The listed sponsor is Carol Fabian, MD, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cognitive Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02517502 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Kansas.
Frequently Asked Questions
What is clinical trial NCT02517502 about?
NCT02517502 is a clinical study titled "Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy". The purpose of this study is to determine if a high dose of DHA begun prior to and continued during neo-adjuvant chemotherapy (chemotherapy given prior to surgery) is likely to prevent or lessen chemotherapy induced cognitive dysfunction.
What is the current status of trial NCT02517502?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2015-07. Estimated completion is 2019-05-03.
What conditions does trial NCT02517502 study?
This clinical trial studies the following conditions: Cognitive Dysfunction.
What interventions are being tested in trial NCT02517502?
The interventions under investigation include: Placebo (DRUG), DHA (DRUG).
Who is sponsoring clinical trial NCT02517502?
This trial is sponsored by Carol Fabian, MD, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02517502 being conducted?
This trial has 2 study locations across Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bicarbonate Administration and Cognitive Function in Midlife and Older Adults With CKD
COMPLETED · Early Phase 1
-
Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits
RECRUITING · NA
-
Surviving Daily Life
RECRUITING
-
The Better, Harder, Faster, Stronger Study
RECRUITING
-
Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment
RECRUITING · NA
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.